R&D News | pharmaphorum

News

ESMO: Roche’s Alecensa claims a first in ALK-positive NSCLC

Roche’s Alecensa has become the first drug in the ALK inhibitor class to significantly improve disease-free survival across all disease stages in a phase 3 trial involving

News

ESMO: Opdivo chases Keytruda in perioperative lung cancer

Just days after MSD claimed an FDA approval for Keytruda as a pre- and post-surgery option for early non-small cell lung cancer (NSCLC), Bristol-Myers Squibb has staked a

News

Beam cuts one in five staffers to conserve cash

Gene-editing company Beam Therapeutics has shifted into reverse, slashing staff and R&D programmes after a period of expansion since its public debut in 2020.

News

£30m scheme to find new antimicrobials launches in UK

The UK has launched a programme to try to accelerate the discovery and development of new diagnostics and treatments for antimicrobial-resistant (AMR) infections, backed w

News

Lilly makes another ADC play, buying Mablink

Eli Lilly has agreed a deal to acquire French antibody-drug conjugate (ADC) specialist Mablink, continuing a series of transactions that build its position in what has bec

News